Price T Rowe Associates Inc. MD Has $10.74 Million Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

Price T Rowe Associates Inc. MD decreased its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 64.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 57,932 shares of the company’s stock after selling 106,173 shares during the period. Price T Rowe Associates Inc. MD owned about 0.19% of Inspire Medical Systems worth $10,740,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Mutual of America Capital Management LLC boosted its stake in Inspire Medical Systems by 1.2% in the fourth quarter. Mutual of America Capital Management LLC now owns 4,540 shares of the company’s stock worth $842,000 after purchasing an additional 55 shares in the last quarter. MML Investors Services LLC grew its stake in shares of Inspire Medical Systems by 0.9% during the fourth quarter. MML Investors Services LLC now owns 7,941 shares of the company’s stock valued at $1,472,000 after purchasing an additional 67 shares during the last quarter. Mariner LLC increased its holdings in shares of Inspire Medical Systems by 1.6% in the fourth quarter. Mariner LLC now owns 4,837 shares of the company’s stock valued at $897,000 after purchasing an additional 77 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Inspire Medical Systems by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 7,879 shares of the company’s stock worth $1,461,000 after buying an additional 79 shares in the last quarter. Finally, Xponance Inc. boosted its position in Inspire Medical Systems by 2.2% in the 4th quarter. Xponance Inc. now owns 3,824 shares of the company’s stock valued at $709,000 after buying an additional 82 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on INSP. Truist Financial decreased their price target on Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating on the stock in a report on Tuesday, February 11th. Robert W. Baird reduced their price objective on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 11th. Wells Fargo & Company cut their price target on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Piper Sandler dropped their price objective on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Finally, Stifel Nicolaus reduced their target price on Inspire Medical Systems from $190.00 to $175.00 and set a “hold” rating on the stock in a report on Monday, April 21st. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Inspire Medical Systems currently has an average rating of “Moderate Buy” and a consensus price target of $218.90.

Insider Buying and Selling

In related news, insider Randy Ban sold 25,584 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the transaction, the insider now owns 7,259 shares of the company’s stock, valued at approximately $1,332,026.50. This trade represents a 77.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO John Rondoni sold 583 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

Inspire Medical Systems Stock Up 1.3 %

Shares of INSP stock opened at $159.89 on Friday. Inspire Medical Systems, Inc. has a 12-month low of $123.00 and a 12-month high of $257.40. The firm has a fifty day moving average of $160.65 and a 200-day moving average of $179.78. The company has a market capitalization of $4.76 billion, a price-to-earnings ratio of 92.42, a P/E/G ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. On average, equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.